Unknown

Dataset Information

0

Ex vivo assays to detect complement activation in complementopathies.


ABSTRACT: In complement-driven thrombotic microangiopathies, failure to regulate complement activation leads to end-organ damage. The modified Ham (mHam) test measures complement-mediated killing of a nucleated cell in vitro but lacks a confirmatory assay and reliable positive controls. We demonstrate that C5b-9 accumulation on the surface of TF1 PIGAnull cells correlates with cell killing in the mHam. We also show that Sialidase treatment of cells or addition of Shiga toxin 1 to human serum serve as a more reliable positive control for the mHam than cobra venom factor or lipopolysaccharide. Simultaneously performing the mHam and measuring C5b-9 accumulation either in GVB++ or GVB0 MgEGTA buffer with the addition of complement pathway specific inhibitors (anti-C5 antibody or a factor D inhibitor, ACH-145951) can be used to localize defects in complement regulation. As more targeted complement inhibitors become available, these assays may aid in the selection of personalized treatments for patients with complement-mediated diseases.

SUBMITTER: Yuan X 

PROVIDER: S-EPMC8609776 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC10470152 | biostudies-literature
| S-EPMC4404182 | biostudies-literature
| S-EPMC3606973 | biostudies-literature
| S-EPMC4133197 | biostudies-literature
2012-04-15 | E-GEOD-36547 | biostudies-arrayexpress
2015-04-27 | E-MTAB-2078 | biostudies-arrayexpress
| S-EPMC10511932 | biostudies-literature
| S-EPMC7011023 | biostudies-literature
| S-EPMC6294360 | biostudies-literature
| S-EPMC4007630 | biostudies-literature